Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Utilization of Medicinal Plants Reported by Korosho
April 1, 2002
- Our Growth Not Enough for Survival: Mr Yokotsuka of Sumitomo
April 1, 2002
- PMS Measures to Be Strengthened in PAL Amendment
April 1, 2002
- Kansai Bio Conference in Kobe Focuses on Regenerative Medicine
April 1, 2002
- DIAGNOSTIC NEWS IN BRIEF
April 1, 2002
- Ono's Elaspol Recommended for Approval by CDFS Department
April 1, 2002
- Makers Are Not Supplying Sufficient Information to Pharmacies: Survey
April 1, 2002
- Meiji Licenses Carbapenem from Wyeth Lederle
April 1, 2002
- Korosho to List All Generics on Website
April 1, 2002
- AJD Develops New Medical Bill Processing System
April 1, 2002
- Suntory, Daiichi to Codevelop Memantine for Alzheimer's Dementia
April 1, 2002
- Hepatitis C Detected in Majority of Users of Non-heated Blood Products
April 1, 2002
- Kraft Opens New Store with Independent Dispensing, Drugstore Divisions
April 1, 2002
- Daiichi Subscribes to Gene Logic's BioExpress
April 1, 2002
- Drugs with Limited Administration Period Announced
April 1, 2002
- OTC NEWS IN BRIEF
April 1, 2002
- Kyorin to Transfer Marketing of Pekiron to Galderma
April 1, 2002
- Korosho to Start Evaluating Its Policy Achievements in April
April 1, 2002
- WORLD NEWS IN BRIEF
April 1, 2002
- Initial Patient Target Achieved for Glivec within 3 Months
April 1, 2002
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…